8-K: Corvus Reports Strong Soquelitinib Data, Extends Cash Runway

Corvus Pharmaceuticals announced positive Phase 1 clinical trial data for soquelitinib in atopic dermatitis, progress across its pipeline, and an extended cash runway into Q4 2026 following warrant exercises.

Summary

• Corvus Pharmaceuticals reported financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update.
• Soquelitinib, the company's selective ITK inhibitor, showed promising interim results from cohort 3 of its Phase 1 clinical trial in moderate to severe atopic dermatitis, demonstrating a 64.8% mean reduction in EASI score at 28 days, compared to 54.6% for cohorts 1-2 combined and 34.4% for placebo.
• Patients in cohort 3 experienced earlier and deeper responses, with clinically meaningful reduction in itch (4-point PP-NRS reduction) in 50% of evaluable patients by day 28, with effects seen as early as day 8.
• Soquelitinib was well tolerated in the Phase 1 trial with no dose limiting toxicities (DLTs) or clinically significant laboratory abnormalities.
• Enrollment is ongoing in extension cohort 4 of the Phase 1 atopic dermatitis trial, studying 24 patients with an 8-week treatment period, with data expected in the fourth quarter of 2025.
• A Phase 2 trial for soquelitinib in atopic dermatitis is on track to initiate before the end of 2025.
• Angel Pharmaceuticals, Corvus's partner in China, received approval to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis in China, which will include a 12-week treatment period and a 400 mg once-daily dose.
• Enrollment continues in the registrational Phase 3 clinical trial of soquelitinib for relapsed/refractory peripheral T cell lymphoma (PTCL), targeting 150 patients.
• Patient enrollment also continues in the Phase 2 clinical trial of soquelitinib for Autoimmune Lymphoproliferative Syndrome (ALPS) in collaboration with NIAID.
• The Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer, in collaboration with the Kidney Cancer Research Consortium, is fully enrolled.
• Angel Pharmaceuticals is evaluating data from its Phase 1/1b clinical trial of mupadolimab in relapsed non-small cell lung cancer.
• As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $74.4 million, up from $52.0 million on December 31, 2024.
• The company received $35.7 million in cash proceeds during Q2 2025 from the exercise of all remaining outstanding common stock warrants, including $2.0 million from warrants exercised by the CEO.
• Corvus expects its cash to fund operations into the fourth quarter of 2026.
• Research and development expenses increased to $7.9 million for Q2 2025, up from $4.1 million for Q2 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib.
• Net loss for Q2 2025 was $8.0 million, compared to a net loss of $4.3 million for Q2 2024.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong clinical data for soquelitinib in atopic dermatitis, significant progress across multiple pipeline programs (PTCL, ALPS), and a substantial improvement in the company's financial runway, extending it into Q4 2026. While net loss increased, it is offset by the cash infusion and clinical advancements, indicating a de-risking of the company's core assets and improved financial stability.

Positives

• Soquelitinib Phase 1 data in atopic dermatitis showed earlier and deeper responses (64.8% mean EASI reduction in cohort 3) and clinically meaningful itch reduction, indicating strong efficacy.
• The safety profile of soquelitinib in the Phase 1 trial was favorable, with no dose limiting toxicities or significant laboratory abnormalities.
• Progress in the atopic dermatitis program includes ongoing enrollment in Phase 1 extension cohort 4 and plans to initiate a Phase 2 trial before year-end 2025.
• Angel Pharmaceuticals' approval to initiate a Phase 1b/2 trial in China expands the clinical development of soquelitinib globally.
• Preclinical data for soquelitinib in systemic sclerosis was recognized as a top 10 abstract at the EULAR 2025 Congress, highlighting broader potential.
• Enrollment continues in the registrational Phase 3 trial for soquelitinib in PTCL, addressing an area with no fully FDA-approved agents.
• The company's cash, cash equivalents, and marketable securities increased to $74.4 million as of June 30, 2025.
• The exercise of common stock warrants generated $35.7 million in cash proceeds, significantly bolstering the company's financial position.
• The company's cash runway is extended into the fourth quarter of 2026, providing financial stability for ongoing operations and clinical development.

Negatives

• Net loss for the three months ended June 30, 2025, increased to $8.0 million from $4.3 million in the same period of 2024.
• Research and development expenses increased by $3.8 million to $7.9 million in Q2 2025 compared to Q2 2024, driven by higher clinical trial and manufacturing costs.

Risks

• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of product candidates is uncertain.
• The accuracy of estimates relating to the initiation and/or completion of preclinical studies and clinical trials and the release of data from such studies and trials may vary.
• Results from preclinical studies and interim data from clinical trials may not be predictive of future results.
• The company's ability to enroll sufficient numbers of patients in its clinical trials is subject to various factors.
• The regulatory process for drug approval is unpredictable and can lead to delays or unfavorable outcomes.
• Regulatory developments in the United States and foreign countries could impact product development and commercialization.
• The costs of clinical trials may exceed expectations, potentially requiring additional capital.
• The company's ability to accurately estimate its cash on hand and its ability to raise additional capital are subject to market conditions and other factors.

Future Outlook

Corvus Pharmaceuticals anticipates reporting data from the extension cohort 4 of the Phase 1 clinical trial for atopic dermatitis in the fourth quarter of 2025. A Phase 2 trial for atopic dermatitis is expected to initiate before the end of 2025. The company's cash resources are projected to fund operations into the fourth quarter of 2026. Angel Pharmaceuticals plans to initiate a Phase 1b/2 trial for soquelitinib in China, further expanding clinical experience. Enrollment will continue in the Phase 3 PTCL and Phase 2 ALPS clinical trials.

Management Comments

• "We are excited by the data reported from our Phase 1 trial of soquelitinib for atopic dermatitis and are advancing its development for this indication on multiple fronts."
• "This includes patient enrollment in the extension cohort 4 of the Phase 1 trial, which is exploring an 8-week treatment period and is on track to report data in the fourth quarter 2025, along with near-final plans for a Phase 2 trial that we expect to initiate before year-end."
• "In China, our partner Angel Pharmaceuticals plans to initiate a separate Phase 1b/2 trial, which will further expand the clinical experience with soquelitinib, including a 12-week treatment period and a 400 mg once-daily dose."
• "In addition, enrollment continues in our Phase 3 registration clinical trial in PTCL and the Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS), reflecting the broader opportunity for ITK inhibition across a range of immune diseases."

Industry Context

This announcement highlights Corvus Pharmaceuticals' continued focus on developing ITK inhibitors for both oncology and immunology, a growing area of interest in the biopharmaceutical industry. The positive Phase 1 data for soquelitinib in atopic dermatitis positions it as a potential new oral therapeutic option in a competitive dermatology market, where current treatments include topical therapies, oral therapies, and systemic injectable biologics. The advancement of soquelitinib in rare diseases like PTCL and ALPS, coupled with FDA Orphan Drug and Fast Track designations, underscores the company's strategy to address unmet medical needs. The collaboration with Angel Pharmaceuticals in China reflects a broader industry trend of globalizing clinical development and leveraging regional partnerships for market access and expanded patient populations.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks. However, the reported 64.8% mean EASI reduction at 28 days for soquelitinib in cohort 3 of the Phase 1 atopic dermatitis trial is a strong early signal, particularly when compared to the 34.4% for placebo in the same trial. This level of response in a Phase 1 setting suggests competitive potential against existing and emerging oral treatments for moderate to severe atopic dermatitis, which often aim for EASI-75 (75% reduction in EASI score) or EASI-90 endpoints in later-stage trials.
• For relapsed/refractory PTCL, the filing notes that there are no FDA fully approved agents based on randomized trials, and median progression-free survival for patients in relapse is typically 3-4 months with overall median survival of 6-12 months. Soquelitinib's Phase 3 registrational trial aims to improve upon these poor outcomes, positioning it against current physician's choice treatments like belinostat or pralatrexate, which represent the standard of care in a challenging disease area.

Related Party Transactions

• Corvus CEO, Dr. Miller, exercised warrants resulting in $2.0 million in cash proceeds to the company.
• Corvus holds a 49.7% equity stake in Angel Pharmaceuticals (excluding 7% reserved for employee stock ownership plan) and has designated three individuals on Angel's five-person Board of Directors, indicating a significant related party relationship through their collaboration and investment.

Stakeholder Impact

• **Shareholders:** Benefit from the extended cash runway, reducing immediate dilution risk, and positive clinical trial data which de-risks key pipeline assets, potentially increasing shareholder value.
• **Patients:** Potential for new, effective treatment options for atopic dermatitis, peripheral T cell lymphoma, and autoimmune lymphoproliferative syndrome, addressing significant unmet medical needs.
• **Employees:** Continued stability and progress in clinical development may foster a positive work environment and job security.
• **Creditors:** Improved cash position and extended runway enhance the company's financial stability and ability to meet obligations.
• **Partners (Angel Pharmaceuticals, NIAID, KCRC):** Continued collaboration and progress in joint clinical trials reinforce the value of these partnerships.

Next Steps

• Report data from the extension cohort 4 of the Phase 1 clinical trial for atopic dermatitis in the fourth quarter of 2025.
• Initiate a Phase 2 clinical trial for soquelitinib in atopic dermatitis before the end of 2025.
• Angel Pharmaceuticals to initiate a Phase 1b/2 clinical trial of soquelitinib for atopic dermatitis in China.
• Continue patient enrollment in the registrational Phase 3 clinical trial of soquelitinib in relapsed/refractory PTCL.
• Continue patient enrollment in the Phase 2 clinical trial of soquelitinib for Autoimmune Lymphoproliferative Syndrome (ALPS).

Key Dates

Recommendation

The filing presents compelling positive developments that significantly enhance Corvus Pharmaceuticals' investment profile. The strong Phase 1 clinical data for soquelitinib in atopic dermatitis, demonstrating superior efficacy and a favorable safety profile, is a major de-risking event for a key pipeline asset. This, combined with the clear path to Phase 2 initiation and a partner-led trial in China, signals robust development momentum. Financially, the $35.7 million from warrant exercises has substantially strengthened the balance sheet, extending the cash runway into Q4 2026, which alleviates near-term funding concerns and reduces potential dilution. The ongoing Phase 3 PTCL trial and other pipeline assets provide additional long-term value. Given the clinical validation and improved financial stability, the company is well-positioned for future growth, making it a strong buy for investors seeking exposure to innovative biopharmaceutical assets.

Keywords

Corvus Pharmaceuticals, Soquelitinib, Atopic Dermatitis, Peripheral T Cell Lymphoma, PTCL, Autoimmune Lymphoproliferative Syndrome, ALPS, ITK inhibitor, Biopharmaceutical, Clinical Trial, Phase 1, Phase 2, Phase 3, Oncology, Immunology, Rare Disease, Nasdaq, CRVS, Ciforadenant, Mupadolimab, Drug Development, Financial Results